Janice Pettie1,2, Allan Burt1, Duleeka W Knipe3, Hazel Torrance4, Margaret Dow1,2, Karen Osinski1,2, Robert Greig1, Diletta Sabatini1, Kate Easterford5, James Dear1,2,6, Michael Eddleston1,2,6. 1. Edinburgh Clinical Toxicology, Royal Infirmary of Edinburgh, Edinburgh, UK. 2. National Poisons Information Service - Edinburgh, Royal Infirmary of Edinburgh, Edinburgh, UK. 3. Population Health Sciences, Bristol Medical School, University of Bristol, UK. 4. Forensic Toxicology Service, Forensic Medicine and Science, University of Glasgow, Glasgow, UK. 5. Emergency Medicine Department, Royal Infirmary of Edinburgh, Edinburgh, UK. 6. Pharmacology, Toxicology, & Therapeutics, University/BHF Centre for Cardiovascular Science, University of Edinburgh, Edinburgh, UK.
Abstract
AIMS: Recreational use of novel psychoactive substance (NPS) has become increasingly common. We aimed to assess the association of national legislation and local trading standards activity with hospital presentations. METHODS: We established observational cohorts of patients with recreational drug toxicity presenting to Edinburgh Royal Infirmary and dying with detectable recreational drugs in Edinburgh. We assessed associations with two temporary class drug-orders (April 2015: methylphenidates, Nov 2015: methiopropamine), the Psychoactive Substances Act (June 2016), and trading standards forfeiture orders (October 2015). RESULTS: The methylphenidate temporary class drug-order was associated with rapid 46.7% (P = 0.002) and 21.0% (P = 0.003) reductions in presentations and admissions, respectively, for NPS drug toxicity, comparing 12 months before with 6 months after. The change was greatest for ethylphenidate toxicity (96.7% reduction in admissions, P < 0.001) that was partly offset by a tripling in synthetic cannabinoid receptor agonist cases (P < 0.001) over the next 6 months. This increase reversed following trading standards activity removing all NPS drugs from local shops in October 2015, associated with 64.3% (P < 0.001) and 83.7% (P < 0.001) reductions in presentations and admissions, respectively, for all NPS drugs over the next 12 months. The effect was sustained and associated with a reduced postmortem detection of stimulant NPS drugs. The two interventions prevented an estimated 557 (95% confidence interval 327-934) NPS admissions during 2016, saving an estimated £303 030 (£177 901-508 133) in hospital costs. CONCLUSIONS: We show here that drug legislation and trading standards activity may be associated with effective and sustained prevention. Widespread adoption of trading standards enforcement, together with focused legislation, may turn the tide against these highly-damaging drugs.
AIMS: Recreational use of novel psychoactive substance (NPS) has become increasingly common. We aimed to assess the association of national legislation and local trading standards activity with hospital presentations. METHODS: We established observational cohorts of patients with recreational drug toxicity presenting to Edinburgh Royal Infirmary and dying with detectable recreational drugs in Edinburgh. We assessed associations with two temporary class drug-orders (April 2015: methylphenidates, Nov 2015: methiopropamine), the Psychoactive Substances Act (June 2016), and trading standards forfeiture orders (October 2015). RESULTS: The methylphenidate temporary class drug-order was associated with rapid 46.7% (P = 0.002) and 21.0% (P = 0.003) reductions in presentations and admissions, respectively, for NPS drug toxicity, comparing 12 months before with 6 months after. The change was greatest for ethylphenidatetoxicity (96.7% reduction in admissions, P < 0.001) that was partly offset by a tripling in synthetic cannabinoid receptor agonist cases (P < 0.001) over the next 6 months. This increase reversed following trading standards activity removing all NPS drugs from local shops in October 2015, associated with 64.3% (P < 0.001) and 83.7% (P < 0.001) reductions in presentations and admissions, respectively, for all NPS drugs over the next 12 months. The effect was sustained and associated with a reduced postmortem detection of stimulant NPS drugs. The two interventions prevented an estimated 557 (95% confidence interval 327-934) NPS admissions during 2016, saving an estimated £303 030 (£177 901-508 133) in hospital costs. CONCLUSIONS: We show here that drug legislation and trading standards activity may be associated with effective and sustained prevention. Widespread adoption of trading standards enforcement, together with focused legislation, may turn the tide against these highly-damaging drugs.
Authors: Douglas B Murray; Stephen Potts; Carole Haxton; Gillian Jackson; Euan A Sandilands; John Ramsey; Malgorzata Puchnarewicz; David W Holt; Atholl Johnston; D Nicholas Bateman; James W Dear Journal: Clin Toxicol (Phila) Date: 2012-01-06 Impact factor: 4.467
Authors: Simon L Hill; Siân C D Harbon; James Coulson; Gillian A Cooper; Gill Jackson; David J Lupton; J Allister Vale; Simon H L Thomas Journal: Emerg Med J Date: 2013-01-24 Impact factor: 2.740
Authors: Janice Pettie; Allan Burt; Duleeka W Knipe; Hazel Torrance; Margaret Dow; Karen Osinski; Robert Greig; Diletta Sabatini; Kate Easterford; James Dear; Michael Eddleston Journal: Br J Clin Pharmacol Date: 2018-07-20 Impact factor: 4.335
Authors: Silja Skogstad Tuv; Marianne Skov-Skov Bergh; Jannike Mørch Andersen; Synne Steinsland; Vigdis Vindenes; Michael H Baumann; Marilyn A Huestis; Inger Lise Bogen Journal: Int J Mol Sci Date: 2021-11-05 Impact factor: 5.923